TY - JOUR
T1 - Substitution therapy for heroin addiction
AU - Bell, James
AU - Dru, Alain
AU - Fischer, Benedikt
AU - Levit, Shabtay
AU - Sarfraz, M. Aamer
PY - 2002
Y1 - 2002
N2 - Substitution treatment for heroin addiction, defined here as maintenance prescribing of opioid agonist drugs to opioid dependent subjects, has increased in the last decade. The recent history of substitution treatment in five countries-Canada, the U.K., Australia, Israel, and France-is reviewed. In all five countries, the critical issues around substitution treatment are similar. The first key issue concerns the balance between making treatment accessible and attractive, and minimizing diversion to the black market. The second issue concerns the role of primary health care in delivering MMT. In general, there has been increasing involvement of primary health care, with training and support for practitioners. However, there remains uncertainty and official ambivalence over whether treatment should be restricted to specialist clinics and practitioners, or available through primary care. Most importantly, underlying these issues is the problem of stigma being associated with both addiction, and with substitution treatment. The underlying problem that treatment is often at odds with community values places enormous strains on substitution treatment, and makes the treatment system vulnerable to shifting community support and abrupt, politically-driven changes in policy.
AB - Substitution treatment for heroin addiction, defined here as maintenance prescribing of opioid agonist drugs to opioid dependent subjects, has increased in the last decade. The recent history of substitution treatment in five countries-Canada, the U.K., Australia, Israel, and France-is reviewed. In all five countries, the critical issues around substitution treatment are similar. The first key issue concerns the balance between making treatment accessible and attractive, and minimizing diversion to the black market. The second issue concerns the role of primary health care in delivering MMT. In general, there has been increasing involvement of primary health care, with training and support for practitioners. However, there remains uncertainty and official ambivalence over whether treatment should be restricted to specialist clinics and practitioners, or available through primary care. Most importantly, underlying these issues is the problem of stigma being associated with both addiction, and with substitution treatment. The underlying problem that treatment is often at odds with community values places enormous strains on substitution treatment, and makes the treatment system vulnerable to shifting community support and abrupt, politically-driven changes in policy.
KW - Buprenorphine
KW - Heroin
KW - Methodone
KW - Substitution treatment
UR - https://www.scopus.com/pages/publications/0036022087
U2 - 10.1081/JA-120004176
DO - 10.1081/JA-120004176
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 12180559
AN - SCOPUS:0036022087
SN - 1082-6084
VL - 37
SP - 1149
EP - 1178
JO - Substance Use and Misuse
JF - Substance Use and Misuse
IS - 8-10
ER -